Udenyca (pegfilgrastim biosimilar) - Coherus
FYB201 (ranibizumab biosimilar) - Amneal, Formycon
CHS-3351 (ranibizumab biosimilar) - Coherus
http://www.globenewswire.com/news-release/2019/11/06/1942561/0/en/Coherus-Acquires-Commercial-Rights-for-Leading-Lucentis-Biosimilar-in-the-United-States.html
 
Nov 6, 2019
 
Prev Next